An observational study in Brain Arteriovenous Malformations, sponsored by Beijing Tiantan Hospital. Recruiting at 4 sites in China. Open to participants aged 3 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by Beijing Tiantan Hospital · Observational
The purpose of this study is to investigate the role of multimodal CT in evaluating and predicting different clinical outcomes in patients with unruptured brain arteriovenous malformations with medical management alone.
This study will be undertaken in the following aspects:
The obtained patient information includes: Baseline information, CT, MRI, DSA (Optional), and follow-up information. Follow-up will be undertaken at 6 months, 12 months, 24 months and 36 months after enrollment with the following primary observation.
Main observation endpoints:
This study is a Long-term, multi-center, prospective registry study, and was supported by China National Key Research and Development Program Project No. 2021YFC2500502.
The purpose of this study is to investigate the role of multimodal Computer Tomography(CT) in evaluating and predicting different clinical outcomes in patients with unruptured brain arteriovenous malformations with medical management alone.
This study will be undertaken in the following aspects:
The obtained patient information includes:
Main observation endpoints:
Inclusion criteria
Exclusion criteria.
141 studies on the registry are indexed under Hemangioma; 16 are open to participants now.
This study's planned enrollment of 200 is above the median of 79 across 56 observational studies indexed under Hemangioma.
Browse Hemangioma studies →Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with the diagnosis of AVM was confirmed with Digital Subtraction Angiography (DSA) , Magnetic Resonance Imaging(MRI), or Computed Tomography Angiography, eligible for enrollment criteria and have images that were acquired without any intervention.
Exclusion Criteria:
Number of participants with rupture events
Arteriovenous malformation rupture during follow-up before treatment
Time frame: 3 years after enrollment
Number of participants with epilepsy Progression
Progression of seizure symptoms during follow-up, including but not limited to more frequent seizures, worsening of symptoms, etc.
Time frame: 3 years after enrollment
Number of participants with new onset neurological dysfunction
New neurological deficits during the follow-up period, including motor deficits, cognitive deficits, etc.
Time frame: 3 years after enrollment
Number of participants receiving treatment
Patients receiving any form of intervention during the follow-up period will stop the follow-up
Time frame: 3 years after enrollment
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tiantan Hospital